Intraperitoneal chemotherapy comes of age

New England Journal of Medicine

Volumn 354, Issue 1, 2006, Pages 77-79

  Cannistra, Stephen A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG ABSORPTION; DRUG RESPONSE; EDITORIAL; HUMAN; NURSING HOME; ONCOLOGY NURSING; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR ACCESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; INFUSIONS, PARENTERAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 30044452365     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058308     Document Type: Editorial

References (12)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
2. McGuire WP III. High-dose chemotherapeutic approaches to ovarian cancer management. Semin Oncol 2000;27:Suppl 7:41-6.
3. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-51.
4. Rothenberg ML, Liu PY, Braly PS, et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 2003;21:1313-9.
5. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
6. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389-94.
7. Benedetti-Panici P, Greggi S, Maneschi F, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol 1993;51:150-4.
8. Walker JL, Armstrong D, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100:27-32.
9. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 2002;20:3944-6.
10. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003;90:637-43. [Erratum, Gynecol Oncol 2003;91:662.]
11. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
12. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.